Evidence map›Paper›PMID 37258796›Full record

ReviewBritish journal of cancer2023

Risk-reducing surgery for individuals with cancer-predisposing germline pathogenic variants and no personal cancer history: a review of current UK guidelines.

Rebecca L McCarthy, Ellen Copson, William Tapper, Helen Bolton, Alex H Mirnezami, J Robert O'Neill, Nimesh N Patel, Marc Tischkowitz, Ramsey I Cutress

Open access · hybridAbstract readReview
In one paragraph

Review in British journal of cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 2 pooled it
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 2 syntheses or guidelines pooled it, 11 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Article
  4. Observational
  5. Review
  6. Article
  7. Article
  8. Hereditary genetic testing and mainstreaming: a guide for surgeons.Annals of the Royal College of Surgeons of England · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Rebecca L McCarthyUniversity Hospital Southampton NHS Trust, Southampton, UK. rebecca.mccarthy7@nhs.net.ORCID 0000-0002-7126-8384
Ellen CopsonUniversity Hospital Southampton NHS Trust, Southampton, UK.ORCID 0000-0001-8994-4056
William TapperUniversity of Southampton Faculty of Medicine Health and Life Sciences, Southampton, UK.
Helen BoltonDepartment of Gynaecological Oncology, Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge, Cambridgeshire, UK.
Alex H MirnezamiUniversity Hospital Southampton NHS Trust, Southampton, UK.
J Robert O'NeillCambridge Oesophagogastric Centre, Addenbrooke's Hospital, Cambridge, Cambridgeshire, UK.
Nimesh N PatelDepartment of Otolaryngology, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
Marc TischkowitzDepartment of Medical Genetics, National Institute for Health Research Cambridge Biomedical Research Centre, University of Cambridge, Cambridge, UK.
Ramsey I CutressUniversity Hospital Southampton NHS Trust, Southampton, UK.
University Hospital Southampton NHS Foundation Trust · GBAddenbrooke's Hospital · GBCambridge University Hospitals NHS Foundation Trust · GBUniversity of Cambridge · GBUniversity of Southampton · GB

Funding

Cancer Research UK C61296/A27223Cancer Research UK CTRQQR-2021\100012Department of Health BRC-1215-20014
6 · The paper itself

Abstract

Identifying healthy carriers of germline pathogenic variants in high penetrance cancer susceptibility genes offers the potential for risk-reducing surgery. The NHS England National Genomic Test Directory offers germline and somatic testing to patients with certain cancers or rare and inherited diseases, or, in some cases, to their relatives. This review summarises current UK guidelines for risk-reducing surgical interventions available for individuals with no personal history of cancer, who are determined to carry germline pathogenic variants. An electronic literature search of NICE guidelines and PubMed citable articles was performed. NICE guidelines are available for bilateral mastectomy and are currently in development for risk-reducing bilateral salpingo-oophorectomy. Guidelines developed with affiliation to, or through relevant British Surgical Societies or international consensus, are available for risk-reducing hysterectomy, polypectomy, gastrectomy, and thyroidectomy. There is a disparity in the development and distribution of national guidelines for interventions amongst tumour types. Whilst we are focusing on UK guidelines, we anticipate they will be relevant much more generally and so of interest to a wider audience including where there are no national guidelines to refer to. We suggest that, as genetic testing becomes rapidly more accessible, guideline development for interventions should be more closely aligned to those for testing.

Indexed as

Breast NeoplasmsFemaleGenetic Predisposition to DiseaseGenetic TestingGerm-Line MutationHumansMastectomyUnited Kingdom

Identifiers

PMID37258796
PMCPMC10403612
OpenAlexW4378806312

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.